Spectral AI appoints new COO to lead operations

DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), a Dallas-based artificial intelligence company specializing in medical diagnostics, has announced the appointment of Stanley Micek as its new Chief Operating Officer. Micek, who has served as the interim COO since May 2024, will now permanently take over the operations of the company, which is currently focused on developing diagnostic tools for wound care. The company, with a market capitalization of approximately $42 million, has shown strong financial discipline, maintaining more cash than debt on its balance sheet according to InvestingPro data.

The company’s board chairman, Dr. J. Michael DiMaio, praised Micek’s leadership and operational expertise, highlighting his significant contribution to the company’s research and development efforts and his role in advancing Spectral AI’s FDA submission process. Micek’s experience includes a tenure as Senior Vice President for Business Development & Strategy at MiMedx and various leadership roles at The Ohio State University Comprehensive Cancer Center.

In his remarks, Micek expressed his commitment to leading the operations team and continuing the progress made from the company’s recent Pivotal Burn Study. He emphasized the importance of the DeepView® System, a predictive device under development that aims to provide clinicians with an objective assessment of a burn wound’s healing potential.

Spectral AI’s DeepView® System is designed to revolutionize wound care management by offering algorithm-driven results that could potentially improve patient outcomes and reduce healthcare costs. The company’s vision for the DeepView® System is to exceed the current standard of care by providing immediate and accurate treatment insights.

The press release also contained forward-looking statements regarding the company’s strategy and financial outlook, cautioning readers about the inherent risks and uncertainties of such statements. Investors are advised to consider these factors carefully and refer to the company’s SEC filings for a more comprehensive understanding of the risks involved.

This announcement is based on a press release statement from Spectral AI, Inc.

In other recent news, Spectral AI reported impressive financial results for the first quarter of 2025, with revenue reaching $6.7 million, surpassing BTIG’s estimate of $4.6 million. The company’s earnings per share (EPS) also exceeded expectations, coming in at $0.12 compared to the anticipated loss of $0.19 per share. Despite this strong performance, Spectral AI is taking steps to reduce operating expenses to conserve cash, as noted by BTIG analyst Ryan Zimmerman. The company has reiterated its full-year 2025 revenue guidance of approximately $21.5 million, a 27.3% decrease year-over-year, primarily due to expected declines in R&D revenue ahead of the U.S. launch of its DeepView product.

BTIG has adjusted its price target for Spectral AI from $3 to $2 but maintained its Buy rating, reflecting confidence in the company’s progress toward key milestones. Spectral AI’s recent advancements include positive data from a U.S. burn trial and preparations for an FDA submission of its DeepView system by the end of the second quarter of 2025, with anticipated approval in early 2026. Additionally, the company has improved its cash position to over $14 million, supported by long-term debt financing. Spectral AI also plans to spin off its intellectual property subsidiary, Spectral IP, into an independent publicly traded company, further strengthening its strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.